Trials / Completed
CompletedNCT01728064
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- PTC Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo capsules |
| DRUG | EPI-743 400 mg | |
| DRUG | EPI-743 200 mg |
Timeline
- Start date
- 2012-12-31
- Primary completion
- 2015-10-31
- Completion
- 2016-02-29
- First posted
- 2012-11-16
- Last updated
- 2020-08-31
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01728064. Inclusion in this directory is not an endorsement.